At the same dose, a 74 kg participant had about 1.4 times the exposure of a 110 kg reference, while a 143 kg participant had about 0.8 times. Weight alone does not set the dose, but it helps explain why the trial mean transfers poorly to bodies outside the studied range
That said, responsible use requires medical supervision
Retatrutide's Phase 2 trial data (Jastreboff et al., NEJM 2023) identified a side-effect profile broadly consistent with other incretin-based therapies: Gastrointestinal : Nausea, vomiting, diarrhoea, and constipation were the most commonly reported adverse effects, particularly during dose escalation
What Is Pentadeca Arginate Peptide (PDA)
Post-surgical recovery: Both may be discussed in theory BPC-157 for local tissue considerations, and CJC-1295/Ipamorelin for systemic recovery
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health